Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Recurrent Adult Brain Tumor: early-phase trial registry

1 of 10 indexed Recurrent Adult Brain Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 1 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Recurrent Adult Brain Tumor: 10 US clinical trials tracked, 1 recruiting.

Recurrent Adult Brain Tumor is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 4 of these trials.

Enrollment posture brief

Registry condition recurrent-adult-brain-tumor

OPEN 1 | RECR 10% | LATE 0 | EARLY 9 | RANK #1724 | SPON 4

Nearest open-share peer: Angina Pectoris (10% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Recurrent Adult Brain Tu (th…10%
Open-enrollment share among volume-matched conditions near Recurrent Adult Brain Tumor

Recurrent Adult Brain Tumor lists 1 open slots (10% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Adult Brain Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Adult Brain Tumor is recruiting below its size-band peers.

    1 of 10 indexed trials (10%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Adult Brain Tumor research.

    City of Hope Medical Center accounts for 4 of 10 trials (40%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Adult Brain Tumor trials plan to enrol fewer than 100 people.

    Median target enrolment is 33 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. Recurrent Adult Brain Tumor research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING 225 participants

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Erasmus Medical Center

NCT06273176

COMPLETED Phase 1 136 participants

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

NCT00045110

COMPLETED Phase 2 56 participants

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

NCT00445588

COMPLETED Phase 2 44 participants

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

National Cancer Institute (NCI)

NCT00980343

COMPLETED Phase 2 33 participants

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Manmeet Ahluwalia, MD

NCT01753713

COMPLETED Phase 1 25 participants

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

City of Hope Medical Center

NCT00638898

COMPLETED Phase 1 25 participants

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Sanjiv Sam Gambhir

NCT01806675

COMPLETED Phase 1 16 participants

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

City of Hope Medical Center

NCT02015819

COMPLETED Phase 1 15 participants

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

City of Hope Medical Center

NCT01172964

COMPLETED Phase 1 7 participants

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

City of Hope Medical Center

NCT01234740

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Named interventions

Most-linked intervention names on Recurrent Adult Brain Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

pharmacological study Other
6 trials
laboratory biomarker analysis Other
5 trials
flucytosine Drug
2 trials
erlotinib hydrochloride Drug
2 trials
gene therapy Biological
1 trials
polymerase chain reaction Other
1 trials
18F-FPPRGD2 Drug
1 trials
18F-fludeoxyglucose (18F-FDG) Drug
1 trials

US sites by state

Facility locations filed on Recurrent Adult Brain Tumor trials. A trial with sites in several states counts in each.

California 8 trials
Pennsylvania 3 trials
Ohio 3 trials
Massachusetts 3 trials
North Carolina 2 trials
Michigan 2 trials
Maryland 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Adult Brain Tumor page

10 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Adult Brain Tumor condition card totals 10 registered trials; most-linked intervention pharmacological study; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.